Name
Acute myeloid leukemia, NOS
Reportable
for cases diagnosed
1978 and later
Primary Site(s)
C421
Primary site must be bone marrow (C421)
Coding Manual:
Hematopoietic Coding Manual (PDF)
Abstractor Notes
Acute myeloid leukemia, NOS is a generic disease description. DCO cases or path report only cases may stay in this classification.
In most cases, NOS histology is only the provisional diagnosis; the physician will run further diagnostic procedures and look for various clinical presentations to identify a more specific disease. Further review of the medical record should be done to look for the tests listed as definitive diagnosis. If no information is found in the medical record, follow-back to the attending physician should be done.
More specific myeloid leukemias include
1. Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15-MKL1 (9911/3)
2. Acute myeloid leukemia with BCR-ABL1 (9912/3) (2021)+
3. Acute myeloid leukemia with biallelic mutation of CEBPA (9878/3) (2021+)
4. Acute myeloid leukemia with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM (9869/3)
5. Acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 (9871/3)
6. Acute myeloid leukemia with maturation (9874/3)
7. Acute myeloid leukemia with minimal differentiation (9872/3)
8. Acute myeloid leukemia with mutated NPM1 (9877/3) (2021+)
9. Acute myeloid leukemia with mutated RUNX1 (9879/3) (2021+)
10. Acute myeloid leukemia with myelodysplasia-related changes (9895/3)
11. Acute myeloid leukemia with t(6;9)(p23;q34.1); DEK-NUP214 (9865/3)
12. Acute myeloid leukemia, t(8;21)(q22;q22.1); RUNX1-RUNX1T1 (9896/3)
13.Acute myeloid leukemia with t(9;11)(p21.3;q23.3); KMT2A-MLLT3 (9897/3)
14. Acute myeloid leukemia without maturation (9873/3)
15. Myeloid leukemia associated with Down syndrome (9898/3)
16. Myeloid/lymphoid neoplasms with PDGFRB rearrangement (9966/3)
When a more specific diagnosis is identified, the histology should be changed to the more specific neoplasm name and code. See the histology tables for more information on NOS and more specific histologies.
This histology should also be used when the diagnosis is "Acute myeloid leukemia with recurrent genetic abnormalities" and there are no specific recurrent genetic abnormalities listed.
Specific AML histologies with recurrent genetic abnormalities include:
9865: Acute myeloid leukemia with t(6;9)(p23;q34.1) DEK-NUP214
9866: Acute promyelocytic leukemia with PML-RARA
9869: Acute myeloid leukemia with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM
9871: Acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
9877: Acute myeloid leukemia with mutated NPM1 (2021+)
9878: Acute myeloid leukemia with biallelic mutation of CEBPA (2021+)
9879: Acute myeloid leukemia with mutated RUNX1 (2021+)
9896: Acute myeloid leukemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1
9897: Acute myeloid leukemia with t(9;11)(p21.3;q23.3); KMT2A-MLLT3
9911: Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15-MKL1
9912: Acute myeloid leukemia with BCR-ABL1 (2021)+
If the leukemia occurs before or simultaneously with Myeloid Sarcoma (9930/3), see M3 and Module 5:PH10.
For more information on acute myeloid leukemia, see the NCI website: http://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq or http://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdqAcute myeloid leukemia, NOS is a generic disease description. DCO cases or path report only cases may stay in this classification.
In most cases, NOS histology is only the provisional diagnosis; the physician will run further diagnostic procedures and look for various clinical presentations to identify a more specific disease. Further review of the medical record should be done to look for the tests listed as definitive diagnosis. If no information is found in the medical record, follow-back to the attending physician should be done.
More specific myeloid leukemias include
1. Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15-MKL1 (9911/3)
2. Acute myeloid leukemia with BCR-ABL1 (9912/3) (2021)+
3. Acute myeloid leukemia with biallelic mutation of CEBPA (9878/3) (2021+)
4. Acute myeloid leukemia with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM (9869/3)
5. Acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 (9871/3)
6. Acute myeloid leukemia with maturation (9874/3)
7. Acute myeloid leukemia with minimal differentiation (9872/3)
8. Acute myeloid leukemia with mutated NPM1 (9877/3) (2021+)
9. Acute myeloid leukemia with mutated RUNX1 (9879/3) (2021+)
10. Acute myeloid leukemia with myelodysplasia-related changes (9895/3)
11. Acute myeloid leukemia with t(6;9)(p23;q34.1); DEK-NUP214 (9865/3)
12. Acute myeloid leukemia, t(8;21)(q22;q22.1); RUNX1-RUNX1T1 (9896/3)
13.Acute myeloid leukemia with t(9;11)(p21.3;q23.3); KMT2A-MLLT3 (9897/3)
14. Acute myeloid leukemia without maturation (9873/3)
15. Myeloid leukemia associated with Down syndrome (9898/3)
16. Myeloid/lymphoid neoplasms with PDGFRB rearrangement (9966/3)
When a more specific diagnosis is identified, the histology should be changed to the more specific neoplasm name and code. See the histology tables for more information on NOS and more specific histologies.
This histology should also be used when the diagnosis is "Acute myeloid leukemia with recurrent genetic abnormalities" and there are no specific recurrent genetic abnormalities listed.
Specific AML histologies with recurrent genetic abnormalities include:
9865: Acute myeloid leukemia with t(6;9)(p23;q34.1) DEK-NUP214
9866: Acute promyelocytic leukemia with PML-RARA
9869: Acute myeloid leukemia with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM
9871: Acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
9877: Acute myeloid leukemia with mutated NPM1 (2021+)
9878: Acute myeloid leukemia with biallelic mutation of CEBPA (2021+)
9879: Acute myeloid leukemia with mutated RUNX1 (2021+)
9896: Acute myeloid leukemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1
9897: Acute myeloid leukemia with t(9;11)(p21.3;q23.3); KMT2A-MLLT3
9911: Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15-MKL1
9912: Acute myeloid leukemia with BCR-ABL1 (2021)+
If the leukemia occurs before or simultaneously with Myeloid Sarcoma (9930/3), see M3 and Module 5:PH10.
For more information on acute myeloid leukemia, see the NCI website: http://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq or http://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdqAcute myeloid leukemia, NOS is a generic disease description. DCO cases or path report only cases may stay in this classification.
Diagnostic Confirmation
This histology can be determined by positive histology (including peripheral blood) with or without genetics and/or immunophenotyping. Review the Definitive Diagnostic Methods, Immunophenotyping and Genetics Data sections below, and the instructions in the Hematopoietic Manual for further guidance on assigning Diagnostic confirmation.
Grade
Not Applicable
Module Rule
See abstractor notes
Alternate Names
Acute granulocytic leukemia
Acute myelocytic leukemia
Acute myelogenous leukemia
Acute myeloid leukemia, NOS
Acute non-lymphocytic leukemia
AML
Definition
Acute myeloid leukemia (AML), NOS, encompasses the cases that do not fulfill the criteria for inclusion in one of the more specified AML entities. The defining criterion for AML is the presence of greater than or equal to 20% myeloid blasts in the peripheral blood or bone marrow.
Definitive Diagnostic Methods
Bone marrow biopsy
Genetic testing
Immunophenotyping
Genetics Data
FLT3-ITD
Immunophenotyping
CD11b
CD13
CD14
CD33 MPO
CD34
CD68
Varies by subclassification
Treatments
Chemotherapy
Hematologic Transplant and/or Endocrine Procedures
Transformations to
None
Transformations from
Same Primaries
Corresponding ICD-9 Codes
205.0 Acute myeloid leukemia
Corresponding ICD-10 Codes
C92.0 Acute myeloid leukemia
Corresponding ICD-10-CM Codes (U.S. only)
C92.0 Acute myeloblastic leukemia (effective October 01, 2015)
Signs and Symptoms
Easy bruising or bleeding
Fatigue
Fever
Petechiae
Shortness of breath
Weakness
Weight loss or loss of appetite
Diagnostic Exams
CT (CAT) scan
Cytogenetic analysis
Immunophenotyping
Lumbar puncture
Peripheral blood smear
Reverse transcription-polymerase chain reaction test (RT-PCR)
Progression and Transformation
None
Epidemiology and Mortality
None
Sources
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds):
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Acute myeloid leukemia and related precursor neoplasms
Pages: 156-157
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Acute myeloid leukemia and related precursor neoplasms
Pages: 156-157
International Classification of Diseases for Oncology, Third Edition, Second Revision. Geneva: World Health Organization, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
National Cancer Institute
Section: General Information About Acute Myeloid Leukemia
Pages: https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq
Section: General Information About Acute Myeloid Leukemia
Pages: https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq